---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-062936"
form_type: "8-K"
ticker: "SPRB"
cik: "0001683553"
company_name: "SPRUCE BIOSCIENCES, INC."
filed_at: "2023-11-13T23:59:59+00:00"
generated_at: "2026-06-08T05:15:45.406763+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Spruce Biosciences Q3 net loss $12.4M; completes enrollment in two key CAH trials

## Summary
- Net loss $12.4M for Q3 2023 vs. $11.4M same period 2022; revenue $3.1M (Kaken collaboration).
- Cash, equivalents, investments $108.0M; expected to fund operations into H1 2025.
- Enrollment completed in CAHptain-205 (pediatric, 30 patients) and CAHmelia-203 (adult, >72 patients).
- CAHmelia-204 enrollment >75% on track for early Q1 2024 completion.
- Topline data expected Q1 2024 for CAHmelia-203 & CAHptain-205; Q3 2024 for CAHmelia-204.

## SEC filing metadata
- accession: 0000950170-23-062936
- form_type: 8-K
- ticker: SPRB
- cik: 0001683553
- company_name: SPRUCE BIOSCIENCES, INC.
- filed_at: 2023-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1683553/000095017023062936/0000950170-23-062936-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1683553/000095017023062936/sprb-20231113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-062936
- JSON: https://secwatch.observer/filing/0000950170-23-062936.json
- Plain text: https://secwatch.observer/filing/0000950170-23-062936.txt

## Key facts
- Earnings Releases
  SPRUCE BIOSCIENCES, INC. reported the third quarter ended September 30, 2023 results: net income $12.4 million.
  - Period: the third quarter ended September 30, 2023
  - Net income: $12.4 million
  - Result: reported results
  source text: Spruce Biosciences Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
  evidence_url: https://www.sec.gov/Archives/edgar/data/1683553/000095017023062936/0000950170-23-062936-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.